NCM
SLN

Nantahala Capital Management’s Silence Therapeutics SLN Stock Holding History

Nantahala Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
1,346,731
-800,000
-37% -$5.63M 0.49% 56
2026
Q1 		$11.3M Buy
2,146,731
+604,304
+39% +$3.33M 0.42% 64
2025
Q4 		$9.38M Buy
1,542,427
+500,000
+48% +$3.2M 0.31% 75
2025
Q3 		$5.41M Hold
1,042,427
– – 0.19% 103
2025
Q2 		$6.05M Hold
1,042,427
– – 0.24% 81
2025
Q1 		$2.94M Sell
1,042,427
-7,249
-0.7% -$35.4K 0.12% 99
2024
Q4 		$7.22M Buy
1,049,676
+849,676
+425% +$11M 0.31% 60
2024
Q3 		$3.64M Hold
200,000
– – 0.18% 83
2024
Q2 		$3.8M Hold
200,000
– – 0.22% 75
2024
Q1 		$4.32M Buy
+200,000
New +$4.35M 0.25% 69

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Nantahala Capital Management's SLN Position: Q2 2026 in Review

Nantahala Capital Management reduced its Silence Therapeutics (SLN) stake by 37% in Q2 2026, selling an estimated $5.63M and leaving 1,346,731 shares worth $14.8M. The position accounts for 0.49% of the portfolio, ranked #56.

Nantahala Capital Management first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Nantahala Capital Management held 1,346,731 shares of Silence Therapeutics worth $14.8M as of Q2 2026.
  • Nantahala Capital Management sold 800,000 Silence Therapeutics shares in Q2 2026, an estimated $5.63M.
  • Silence Therapeutics made up 0.49% of Nantahala Capital Management's portfolio in Q2 2026, its #56 holding.
  • Nantahala Capital Management first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.